Screener
Kura Oncology KURA Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net Loss | $(73,333) | $(57,429) |
| Net loss per share, basic and diluted | $(0.83) | $(0.66) |
| Weighted average number of shares used in computing net loss per share, basic and diluted | 88,610 | 87,415 |
| Comprehensive Loss | ||
| Net loss | $(73,333) | $(57,429) |
| Other comprehensive income (loss) | ||
| Unrealized gain (loss) on short-term investments | (1,404) | 210 |
| Comprehensive loss | $(74,737) | $(57,219) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's comprehensive income (loss), net of tax, attributable to parent?
- Kura Oncology (KURA) reported comprehensive income (loss), net of tax, attributable to parent of -$74.74M in Q1 2026.
- How has Kura Oncology's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Kura Oncology's comprehensive income (loss), net of tax, attributable to parent decreased by 30.6% year-over-year, from -$57.22M to -$74.74M.
- What is the long-term trend for Kura Oncology's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Kura Oncology's comprehensive income (loss), net of tax, attributable to parent has grown at a 20.4% compound annual growth rate (CAGR), from -$132.3M to -$278.41M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, including net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a broader view of the company's financial performance beyond traditional net income by incorporating market-related adjustments. This figure is essential for assessing the total impact of economic events on the company's comprehensive financial health.
Ask your AI about Kura Oncology's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude